New insulin algorithm aims to simplify diabetes management

NCT ID NCT07593625

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a next-generation automated insulin delivery system (Omnipod M) in up to 40 adults with type 1 diabetes. The goal is to see if the system safely improves blood sugar control by reducing dangerously low and high levels. Participants will use the device during hotel and outpatient periods, and researchers will compare glucose readings to their usual care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Otago

    Christchurch, 8140, New Zealand

    Contact

    Contact Email: •••••@•••••